SOURCE: Ablynx

September 12, 2008 12:08 ET

Publication in Accordance With the Act of 2 May 2007 Regarding the Publication of Major Shareholdings

GHENT, BELGIUM--(Marketwire - September 12, 2008) - Ablynx (Euronext Brussels: ABLX), a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, published today the information in accordance with Articles 15, 18 and 29 of the Belgian Act of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Act").

In accordance with the Act, Ablynx NV published the following information:

| Total amount of the capital of the Company : | EUR  68,361,045.84|
| Total number of voting securities:           |         36,438,959|
| Total number of voting rights (denominator): |         36,438,959|

Ablynx NV has an aggregate of 3,532,297 outstanding warrants, 3,521,584 warrants of which entitle their holders to an aggregate of 1,760,792 shares (two warrants giving right to subscribe for one share) and 10,713 warrants of which entitle their holders to an aggregate of 10,713 shares (one warrant giving right to subscribe for one share). The aggregate number of voting rights that can be obtained upon exercise of the outstanding warrants amounts to 1,771,505.

Ablynx NV has not issued any other rights to subscribe for voting securities that have not yet been issued or any shares without voting rights. The voting securities of Ablynx NV are not divided into categories.

Ablynx NV also announced that, in accordance with Article 18, § 1 of the Act, its Articles of Association provide for an additional notification threshold of 3%.

This information is valid as of 12 September 2008. In accordance with the Act, changes to the information set out above will be published ultimately by the end of the calendar month during which the relevant change has occurred.


About Ablynx

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. The Company currently has over 180 employees. Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November 2007.

Ablynx is developing a portfolio of Nanobody®-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Nanobodies® have been generated against more than 100 different disease targets. Efficacy data has been obtained in 20 in vivo models for Nanobodies® against a range of different targets. Its lead programme, ALX-0081, a novel anti-thrombotic is in a multi-dose Phase 1b study in patients. ALX-0681, also a novel anti-thrombotic, is in advanced preclinical development.

Ablynx has an extensive patent position in the field of Nanobodies® for healthcare applications. It has exclusive and worldwide rights to more than 50 families of granted patents and pending patent applications, including the Hamers patents covering the basic structure, composition, preparation and uses of Nanobodies®. Ablynx has ongoing research collaborations and significant partnerships with some of the major pharmaceutical companies, including Boehringer Ingelheim, Wyeth Pharmaceuticals and Novartis. Ablynx is building a diverse and broad portfolio of therapeutic Nanobodies® through these collaborations as well as through its own internal discovery programmes. The Company dedicates 70% of its R&D staff to rapidly build its internal portfolio of Nanobodies® and has only partnered less than 2% of those targets accessible to Nanobodies®. Ablynx announced final Phase I data from its lead programme, an anti-thrombotic (ALX-0081) in December 2007 and another programme, which is partnered, is in advanced preclinical development.

Nanobody® is a registered trademark of Ablynx NV.

Copyright © Hugin AS 2008. All rights reserved.

Complete PDF version of the press release in English:

Contact Information

  • For more information, please contact:

    Wim Ottevaere
    Chief Financial Officer
    t: +32 9 262 00 08
    e: Email Contact